Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc    MRK

MERCK & CO., INC

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/30/2020 03/31/2020 04/01/2020 04/02/2020 04/03/2020 Date
76.95(c) 76.94(c) 73.8(c) 76.87(c) 76.25(c) Last
15 079 481 14 390 485 11 130 985 12 255 544 9 578 803 Volume
+7.28% -0.01% -4.08% +4.16% -0.81% Change
More quotes
Financials (USD)
Sales 2020 49 561 M
EBIT 2020 17 774 M
Net income 2020 13 084 M
Debt 2020 14 561 M
Yield 2020 3,13%
Sales 2021 51 631 M
EBIT 2021 19 269 M
Net income 2021 14 344 M
Debt 2021 11 124 M
Yield 2021 3,36%
P/E ratio 2020 15,0x
P/E ratio 2021 13,8x
EV / Sales2020 4,23x
EV / Sales2021 3,99x
Capitalization 195 B
More Financials
Company
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory,... 
Sector
Pharmaceuticals
Calendar
04/18Presentation
More about the company
Surperformance© ratings of Merck & Co., Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK & CO., INC
05:17aSEATTLE GENETICS : Announces Potential Accelerated Approval Pathway in the U.S. ..
AQ
05:17aMERCK : Announces KEYTRUDA Significantly Improved Progression-Free Survival as F..
AQ
04/02Pfizer Inc. - Medical Professionals across Merck & Co., Inc., Pfizer Inc., an..
AQ
04/02MERCK : Keytruda Hits a Main Endpoint in Colorectal Cancer Study
DJ
04/02MERCK : Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-F..
BU
04/02MERCK : to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 2..
BU
03/31MERCK : Intensity Therapeutics Reports Safety Results from First Cohort of the K..
AQ
03/30PDS BIOTECHNOLOGY : Reports Full Year 2019 Financial Results and Provides Busine..
AQ
03/28MERCK : Investigational Drug Vericiguat Significantly Reduced the Risk of the Co..
BU
03/25MERCK : to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
BU
03/23MERCK : Recommends Rejection of TRC Capital's 'Mini-Tender' Offer
AQ
03/23MERCK : Donates Half a Million Protective Masks to New York City
DJ
03/22MERCK : Donates a Half a Million Masks to Support COVID-19 Emergency Response in..
BU
03/20MERCK : Recommends Rejection of TRC Capital's “Mini-Tender” Offer
BU
03/20EISAI : Positive Results from Registrational Study of LENVIMA and KEYTRUDA in Ad..
AQ
More news
News in other languages on MERCK & CO., INC
04/02MERCK : données positives dans le cancer colorectal
03/28Bayer stellt detaillierte Phase-III-Studiendaten zum Herzmittel Vericiguat vo..
03/13MERCK AND COMPANY : Ex-dividend day for
03/12MERCK : partenariat prolongé avec la biotech Sutro
03/08WOCHENAUSBLICK : Corona-Kater bereitet weiter Kopfschmerzen
More news
Stock Trading Strategies
MERCK & CO., INC - 03/26
Good timing to go long again
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC
Duration : Period :
Merck & Co., Inc Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 95,63  $
Last Close Price 76,87  $
Spread / Highest target 39,2%
Spread / Average Target 24,4%
Spread / Lowest Target 11,9%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC-16.16%195 141
JOHNSON & JOHNSON-8.72%345 705
ROCHE HOLDING AG2.77%277 060
NOVARTIS-12.10%187 703
PFIZER, INC.-14.14%181 075
NOVO NORDISK A/S5.61%141 503